Douglas I. Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Douglas I. Walker has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Dean P. Jones
Emory University School of Medicine
11 shared publications Dean P. Jones
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, United States
6 shared publications- Anna S. Young
Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA
5 shared publications - Roel Vermeulen
Institute for Risk Assessment Sciences, Utrecht University , Utrecht
5 shared publications - Damaskini Valvi
Department of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 shared publications - David V. Conti
Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
A Scalable Method for Quantitation of Per-and Polyfluoroalkyl Substances in Human Milk
Breastfeeding is a major route of early-life exposure to per- and polyfluoroalkyl substances (PFAS), yet population-level characterization of this exposure remains limited by the lack of sensitive, high-throughput methods to quantitate PFAS in human milk. To date, PFAS analysis in human milk has required large volumes (1−5 mL) and labor-intensive workflows that are unsuitable for large-scale, population-level biomonitoring. We developed and validated a semi-automated, high-throughput workflow for quantitating 23 legacy and replacement PFAS in 300 μL of human milk, enabling analysis of 72 samples per 20 h batch. Human milk and quality control (QC) samples are processed in 96-well format using an Opentrons Flex automated liquid-handling system with enhanced matrix removal (EMR) mixed-mode matrix cleanup and analyzed by liquid chromatography with high-resolution mass spectrometry (LC-HRMS). Method detection limits ranged from 0.53 to 9.19 pg/mL, with 22 compounds achieving limits of quantitation ≤5 pg/mL. Average accuracy was 93 ± 10% at 5 pg/mL and 90−98% at higher spiking levels. Applied to paired human milk samples collected at 1 and 6 months postpartum from 36 mothers, the method detected 4 PFAS above the LOQ in ≥50% of mothers at one or both time points. Their concentrations showed compound-specific changes, yet their summed concentration remained unchanged. Short-chain PFAS were quantifiable less consistently, with detection frequency shifting notably between time points. This scalable, low-volume workflow enables high-throughput quantitation of PFAS in human milk and supports large-scale biomonitoring of early-life exposure, with implications for exposure assessment, epidemiologic studies, and public health guidance.
- 11 November 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
Open AccessA Scalable Method for Quantitation of Per-and Polyfluoroalkyl Substances in Human Milk
Breastfeeding is a major route of early-life exposure to per- and polyfluoroalkyl substances (PFAS), yet population-level characterization of this exposure remains limited by the lack of sensitive, high-throughput methods to quantitate PFAS in human milk. To date, PFAS analysis in human milk has required large volumes (1−5 mL) and labor-intensive workflows that are unsuitable for large-scale, population-level biomonitoring. We developed and validated a semi-automated, high-throughput workflow for quantitating 23 legacy and replacement PFAS in 300 μL of human milk, enabling analysis of 72 samples per 20 h batch. Human milk and quality control (QC) samples are processed in 96-well format using an Opentrons Flex automated liquid-handling system with enhanced matrix removal (EMR) mixed-mode matrix cleanup and analyzed by liquid chromatography with high-resolution mass spectrometry (LC-HRMS). Method detection limits ranged from 0.53 to 9.19 pg/mL, with 22 compounds achieving limits of quantitation ≤5 pg/mL. Average accuracy was 93 ± 10% at 5 pg/mL and 90−98% at higher spiking levels. Applied to paired human milk samples collected at 1 and 6 months postpartum from 36 mothers, the method detected 4 PFAS above the LOQ in ≥50% of mothers at one or both time points. Their concentrations showed compound-specific changes, yet their summed concentration remained unchanged. Short-chain PFAS were quantifiable less consistently, with detection frequency shifting notably between time points. This scalable, low-volume workflow enables high-throughput quantitation of PFAS in human milk and supports large-scale biomonitoring of early-life exposure, with implications for exposure assessment, epidemiologic studies, and public health guidance.
- Open Access
- 5 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study
Purpose: Although mechanistic evidence suggests that some per- and polyfluoroalkyl substances (PFASs) may be carcinogenic, epidemiologic findings for PFAS and breast cancer remain inconsistent, partly because of differing study designs and limited evaluation by hormone receptor status. Methods: We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants. We oversampled estrogen receptor (ER)–negative cases (324 ER-negative, 1,120 ER-positive) to improve statistical power. Seventeen PFASs were quantified in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry. Sampling-weighted Cox models were used to estimate associations with overall breast cancer incidence and by hormone receptor status, adjusting for confounders and coexposures. We conducted a meta-analysis of seven studies with prediagnostic blood PFAS measurements. Results: We observed associations between certain PFAS and ER-negative tumors. Positive associations were observed for perfluoro-n-octanoic acid (PFOA; hazard ratio [HR] Q4 v Q1 , 1.67 [95% CI, 1.10 to 2.53], P trend = .09), perfluorooctane-1-sulfonic acid (PFOS; HR Q4 v Q1 , 1.93 [95% CI, 1.15 to 3.22], P trend = .01), and potentially n-methylperfluoro-1-octanesulfonamidoacetic acid (N-MeFOSAA; HR Q4 v Q1 , 1.42 [95% CI, 0.99 to 2.04], P trend = .12). By contrast, perfluoro-n-tridecanoic acid was inversely associated with ER-negative tumors (PFTrDA; HR Q4 v Q1 , 0.63 [95% CI, 0.41 to 0.97], P trend = .05). Perfluorooctane sulfonamide (PFOSA), which was infrequently detected (6.9%), was positively associated with ER+ tumors (HR detectable v nondetectable , 1.36 [95% CI, 1.03 to 1.81]). The meta-analysis further supported associations for both PFOA (relative risk [RR], 1.30 [95% CI, 1.05 to 1.62]) and PFOS with ER-negative breast cancer (RR, 1.20 [95% CI, 0.91 to 1.58]). Conclusion: Findings from this large prospective study, together with meta-analyses, suggest that PFOA and PFOS may increase ER-negative breast cancer risk. Given the widespread exposure to PFAS and limited established risk factors for ER-negative tumors, these results have important public health implications.
- 5 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Open AccessPer- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study
Purpose: Although mechanistic evidence suggests that some per- and polyfluoroalkyl substances (PFASs) may be carcinogenic, epidemiologic findings for PFAS and breast cancer remain inconsistent, partly because of differing study designs and limited evaluation by hormone receptor status. Methods: We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants. We oversampled estrogen receptor (ER)–negative cases (324 ER-negative, 1,120 ER-positive) to improve statistical power. Seventeen PFASs were quantified in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry. Sampling-weighted Cox models were used to estimate associations with overall breast cancer incidence and by hormone receptor status, adjusting for confounders and coexposures. We conducted a meta-analysis of seven studies with prediagnostic blood PFAS measurements. Results: We observed associations between certain PFAS and ER-negative tumors. Positive associations were observed for perfluoro-n-octanoic acid (PFOA; hazard ratio [HR] Q4 v Q1 , 1.67 [95% CI, 1.10 to 2.53], P trend = .09), perfluorooctane-1-sulfonic acid (PFOS; HR Q4 v Q1 , 1.93 [95% CI, 1.15 to 3.22], P trend = .01), and potentially n-methylperfluoro-1-octanesulfonamidoacetic acid (N-MeFOSAA; HR Q4 v Q1 , 1.42 [95% CI, 0.99 to 2.04], P trend = .12). By contrast, perfluoro-n-tridecanoic acid was inversely associated with ER-negative tumors (PFTrDA; HR Q4 v Q1 , 0.63 [95% CI, 0.41 to 0.97], P trend = .05). Perfluorooctane sulfonamide (PFOSA), which was infrequently detected (6.9%), was positively associated with ER+ tumors (HR detectable v nondetectable , 1.36 [95% CI, 1.03 to 1.81]). The meta-analysis further supported associations for both PFOA (relative risk [RR], 1.30 [95% CI, 1.05 to 1.62]) and PFOS with ER-negative breast cancer (RR, 1.20 [95% CI, 0.91 to 1.58]). Conclusion: Findings from this large prospective study, together with meta-analyses, suggest that PFOA and PFOS may increase ER-negative breast cancer risk. Given the widespread exposure to PFAS and limited established risk factors for ER-negative tumors, these results have important public health implications.
- Open Access
- 2 June 2026
- Published by American Chemical Society (ACS) in ChemRxiv
A Scalable Method for Quantitation of Per-and Polyfluoroalkyl Substances in Human Milk
- 2 June 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Scalable Method for Quantitation of Per-and Polyfluoroalkyl Substances in Human Milk
- 7 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1110-1119
Prediagnostic Plasma Metabolite Profiles and Prediction of Hepatocellular Carcinoma Risk: The Multiethnic Cohort
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and often arises in cirrhosis cases. Current surveillance methods, including ultrasonography and α-fetoprotein, have limited sensitivity for early detection. Blood metabolomics may improve HCC risk prediction. We aimed to identify pre-diagnostic plasma metabolites associated with HCC risk and evaluate whether cirrhosis-related metabolites enhance prediction beyond established risk factors in a multiethnic population. Methods: We analyzed data from a nested case-control study with pre-diagnostic blood samples in the Multiethnic Cohort, including 240 HCC cases, 151 cirrhosis cases, and individually matched controls. Metabolome-wide association studies and pathway enrichment analyses were performed, followed by feature selection in the cirrhosis samples to construct HCC prediction models. Results: Of 294 metabolites analyzed, 53 were significantly associated with HCC after false discovery rate correction (odds ratios: 0.25–3.93). Pathway analyses highlighted perturbations in lipid and amino acid metabolism. Two cirrhosis-associated metabolites, glutamate and glycochenodeoxycholate, were consistently selected and improved HCC prediction. Adding these metabolites to known risk factors (age, sex, race/ethnicity, study area, BMI, smoking, alcohol consumption, and diabetes) increased the AUC from 0.64 to 0.73 (P < 0.001). Conclusions: Pre-diagnostic metabolomic profiling revealed metabolic alterations linked to HCC risk, emphasizing dysregulated amino acid and bile acid pathways within the cirrhosis context. Impact: Glutamate and glycochenodeoxycholate improved HCC risk prediction beyond established factors, supporting biologically plausible links between hepatic metabolic dysfunction and hepatocarcinogenesis. These findings highlight the potential of metabolomic biomarkers to enhance surveillance and risk stratification among patients with cirrhosis.
- 7 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1110-1119
Prediagnostic Plasma Metabolite Profiles and Prediction of Hepatocellular Carcinoma Risk: The Multiethnic Cohort
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and often arises in cirrhosis cases. Current surveillance methods, including ultrasonography and α-fetoprotein, have limited sensitivity for early detection. Blood metabolomics may improve HCC risk prediction. We aimed to identify pre-diagnostic plasma metabolites associated with HCC risk and evaluate whether cirrhosis-related metabolites enhance prediction beyond established risk factors in a multiethnic population. Methods: We analyzed data from a nested case-control study with pre-diagnostic blood samples in the Multiethnic Cohort, including 240 HCC cases, 151 cirrhosis cases, and individually matched controls. Metabolome-wide association studies and pathway enrichment analyses were performed, followed by feature selection in the cirrhosis samples to construct HCC prediction models. Results: Of 294 metabolites analyzed, 53 were significantly associated with HCC after false discovery rate correction (odds ratios: 0.25–3.93). Pathway analyses highlighted perturbations in lipid and amino acid metabolism. Two cirrhosis-associated metabolites, glutamate and glycochenodeoxycholate, were consistently selected and improved HCC prediction. Adding these metabolites to known risk factors (age, sex, race/ethnicity, study area, BMI, smoking, alcohol consumption, and diabetes) increased the AUC from 0.64 to 0.73 (P < 0.001). Conclusions: Pre-diagnostic metabolomic profiling revealed metabolic alterations linked to HCC risk, emphasizing dysregulated amino acid and bile acid pathways within the cirrhosis context. Impact: Glutamate and glycochenodeoxycholate improved HCC risk prediction beyond established factors, supporting biologically plausible links between hepatic metabolic dysfunction and hepatocarcinogenesis. These findings highlight the potential of metabolomic biomarkers to enhance surveillance and risk stratification among patients with cirrhosis.
- 1 December 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (12) , 2183-2196
Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents
BACKGROUND: Emerging omics approaches, including metabolomics and proteomics, can be integrated into obesity treatment for better blood pressure management. We tested whether preoperative metabolomic and proteomic profiles predict long-term elevated blood pressure (EBP) changes better than known risk factors in adolescents undergoing bariatric surgery. METHODS: We included 108 participants from the Teen-LABS (Teen-Longitudinal Assessment of Bariatric Surgery). Plasma untargeted metabolomics (via liquid chromatography with high-resolution mass spectrometry) and Olink proteomics were assessed pre surgery. An elastic net model with stability selection was used to identify features predictive of EBP reductions 5 years post surgery. Models including identified metabolites, proteins, and known risk factors (age, sex, race, clinical sites, parents’ education level, body mass index, systolic blood pressure, and diastolic blood pressure at baseline) were compared with known-risk-factors-only models. For biological relevance, the consistency of association directions was examined in a multiethnic non-interventional adolescent cohort (n=79). RESULTS: Metabolite-based models and protein-based models with known risk factors each outperformed known-risk- factors-only models in predicting EBP reductions ( P <0.01). Higher levels of 4 metabolites (uric acid, taurocholic acid, nonadecanoic acid, and cystine) were consistently associated with reduced likelihood of EBP improvement or blood pressure improvement across cohorts. SERPINA11 (serine protease inhibitor, clade A, member 11), ICAM5 (intercellular adhesion molecule 5), and TINAGL1 (tubulointerstitial nephritis antigen-like 1) demonstrated consistent associations in both cohorts. CONCLUSIONS: This is the first study identifying potential preoperative biomarkers for EBP reductions in adolescents following bariatric surgery. Integrating metabolomics and proteomics with known risk factors substantially improved predictive models compared with known-risk-factors-only models. Larger and more diverse cohorts are needed to confirm these findings and whether identified features are associated with other blood pressure treatments.
- 1 December 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (12) , 2183-2196
Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents
BACKGROUND: Emerging omics approaches, including metabolomics and proteomics, can be integrated into obesity treatment for better blood pressure management. We tested whether preoperative metabolomic and proteomic profiles predict long-term elevated blood pressure (EBP) changes better than known risk factors in adolescents undergoing bariatric surgery. METHODS: We included 108 participants from the Teen-LABS (Teen-Longitudinal Assessment of Bariatric Surgery). Plasma untargeted metabolomics (via liquid chromatography with high-resolution mass spectrometry) and Olink proteomics were assessed pre surgery. An elastic net model with stability selection was used to identify features predictive of EBP reductions 5 years post surgery. Models including identified metabolites, proteins, and known risk factors (age, sex, race, clinical sites, parents’ education level, body mass index, systolic blood pressure, and diastolic blood pressure at baseline) were compared with known-risk-factors-only models. For biological relevance, the consistency of association directions was examined in a multiethnic non-interventional adolescent cohort (n=79). RESULTS: Metabolite-based models and protein-based models with known risk factors each outperformed known-risk- factors-only models in predicting EBP reductions ( P <0.01). Higher levels of 4 metabolites (uric acid, taurocholic acid, nonadecanoic acid, and cystine) were consistently associated with reduced likelihood of EBP improvement or blood pressure improvement across cohorts. SERPINA11 (serine protease inhibitor, clade A, member 11), ICAM5 (intercellular adhesion molecule 5), and TINAGL1 (tubulointerstitial nephritis antigen-like 1) demonstrated consistent associations in both cohorts. CONCLUSIONS: This is the first study identifying potential preoperative biomarkers for EBP reductions in adolescents following bariatric surgery. Integrating metabolomics and proteomics with known risk factors substantially improved predictive models compared with known-risk-factors-only models. Larger and more diverse cohorts are needed to confirm these findings and whether identified features are associated with other blood pressure treatments.
- Open Access
- 12 September 2025
- Published by Elsevier in Environment International
- Vol. 203, 109787
Integrated chemical exposome–metabolome profiling of follicular fluid and associations with fertility outcomes during assisted reproduction
- 12 September 2025
- Published by Elsevier in Environment International
- Vol. 203, 109787
Open AccessIntegrated chemical exposome–metabolome profiling of follicular fluid and associations with fertility outcomes during assisted reproduction
- Open Access
- 6 June 2025
- Published by Elsevier in Environment International
- Vol. 201, 109590
Novel and legacy per- and polyfluoroalkyl substances in humans: Long-term temporal variability and metabolic perturbations
- 6 June 2025
- Published by Elsevier in Environment International
- Vol. 201, 109590
Open AccessNovel and legacy per- and polyfluoroalkyl substances in humans: Long-term temporal variability and metabolic perturbations
- Open Access
- 22 January 2025
- Published by Oxford University Press (OUP) in Exposome
- Vol. 5 (1) , osaf010
A statistical workflow for analyzing the untargeted chemical exposome and metabolome in epidemiologic studies using high-dimensional mixture methods
Humans are exposed to upwards of thousands of chemicals simultaneously, but research has traditionally focused on the health effects of only one chemical at a time. Single-chemical analyses not only underestimate total health risk, but also ignore bias from multicollinearity and co-exposure confounding between chemicals. Advanced statistical mixture methods address these challenges and allow us to both estimate the cumulative health effect of chemical mixtures and identify the strongest chemical contributors. At the same time, untargeted chemical exposome profiling through high-resolution mass spectrometry (HRMS) now supports measurement of over 100,000 chemical signals in biospecimens. However, most mixture methods cannot evaluate untargeted exposome data containing more chemical variables than samples. Weighted quantile sum regression with its recent random subsets implementation (WQSRS) is a unique, statistically powerful mixture method for high-dimensional exposome data. It estimates weights of chemicals towards the mixture index over many different repetitions in which only a small random subset of chemicals is used at a time, thus de-correlating data and avoiding overfitting. In this paper, we discuss our statistical workflow and important considerations for the application of WQSRS to exposome epidemiology, including manual quantization for non-detects, custom repeated holdouts for matched data, pre-selection of exogenous chemicals, parameter decisions, interpretation options, and visualizations. We then describe its application to functional pathway enrichment analysis with integrated exposome-metabolome data to explore underlying biological mechanisms. These data science approaches will enable exposome epidemiology to discover previously unknown risk factors, estimate cumulative health risk from total chemical mixtures, and gain mechanistic insight.
- 22 January 2025
- Published by Oxford University Press (OUP) in Exposome
- Vol. 5 (1) , osaf010
Open AccessA statistical workflow for analyzing the untargeted chemical exposome and metabolome in epidemiologic studies using high-dimensional mixture methods
Humans are exposed to upwards of thousands of chemicals simultaneously, but research has traditionally focused on the health effects of only one chemical at a time. Single-chemical analyses not only underestimate total health risk, but also ignore bias from multicollinearity and co-exposure confounding between chemicals. Advanced statistical mixture methods address these challenges and allow us to both estimate the cumulative health effect of chemical mixtures and identify the strongest chemical contributors. At the same time, untargeted chemical exposome profiling through high-resolution mass spectrometry (HRMS) now supports measurement of over 100,000 chemical signals in biospecimens. However, most mixture methods cannot evaluate untargeted exposome data containing more chemical variables than samples. Weighted quantile sum regression with its recent random subsets implementation (WQSRS) is a unique, statistically powerful mixture method for high-dimensional exposome data. It estimates weights of chemicals towards the mixture index over many different repetitions in which only a small random subset of chemicals is used at a time, thus de-correlating data and avoiding overfitting. In this paper, we discuss our statistical workflow and important considerations for the application of WQSRS to exposome epidemiology, including manual quantization for non-detects, custom repeated holdouts for matched data, pre-selection of exogenous chemicals, parameter decisions, interpretation options, and visualizations. We then describe its application to functional pathway enrichment analysis with integrated exposome-metabolome data to explore underlying biological mechanisms. These data science approaches will enable exposome epidemiology to discover previously unknown risk factors, estimate cumulative health risk from total chemical mixtures, and gain mechanistic insight.
- Open Access
- 19 December 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
The need for a cancer exposome atlas: a scoping review
Background: Despite advances in understanding genetic susceptibility to cancer, much of cancer heritability remains unidentified. At the same time, the makeup of industrial chemicals in our environment only grows more complex. This gap in knowledge on cancer risk has prompted calls to expand cancer research to the comprehensive, discovery-based study of nongenetic environmental influences, conceptualized as the “exposome.” Methods: Our scoping review aimed to describe the exposome and its application to cancer epidemiology and to study design limitations, challenges in analytical methods, and major unmet opportunities in advanced exposome profiling methods that allow the quantification of complex chemical exposure profiles in biological matrices. To evaluate progress on incorporating measurements of the exposome into cancer research, we performed a review of such “cancer exposome” studies published through August 2023. Results: We found that only 1 study leveraged untargeted chemical profiling of the exposome as a method to measure tens of thousands of environmental chemicals and identify prospective associations with future cancer risk. The other 13 studies used hypothesis-driven exposome approaches that targeted a set of preselected lifestyle, occupational, air quality, social determinant, or other external risk factors. Many of the included studies could only leverage sample sizes with less than 400 cancer cases (67% of nonecologic studies) and exposures experienced after diagnosis (29% of studies). Six cancer types were covered, most commonly blood (43%), lung (21%), or breast (14%) cancer. Conclusion: The exposome is underutilized in cancer research, despite its potential to unravel complex relationships between environmental exposures and cancer and to inform primary prevention.
- 19 December 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
Open AccessThe need for a cancer exposome atlas: a scoping review
Background: Despite advances in understanding genetic susceptibility to cancer, much of cancer heritability remains unidentified. At the same time, the makeup of industrial chemicals in our environment only grows more complex. This gap in knowledge on cancer risk has prompted calls to expand cancer research to the comprehensive, discovery-based study of nongenetic environmental influences, conceptualized as the “exposome.” Methods: Our scoping review aimed to describe the exposome and its application to cancer epidemiology and to study design limitations, challenges in analytical methods, and major unmet opportunities in advanced exposome profiling methods that allow the quantification of complex chemical exposure profiles in biological matrices. To evaluate progress on incorporating measurements of the exposome into cancer research, we performed a review of such “cancer exposome” studies published through August 2023. Results: We found that only 1 study leveraged untargeted chemical profiling of the exposome as a method to measure tens of thousands of environmental chemicals and identify prospective associations with future cancer risk. The other 13 studies used hypothesis-driven exposome approaches that targeted a set of preselected lifestyle, occupational, air quality, social determinant, or other external risk factors. Many of the included studies could only leverage sample sizes with less than 400 cancer cases (67% of nonecologic studies) and exposures experienced after diagnosis (29% of studies). Six cancer types were covered, most commonly blood (43%), lung (21%), or breast (14%) cancer. Conclusion: The exposome is underutilized in cancer research, despite its potential to unravel complex relationships between environmental exposures and cancer and to inform primary prevention.
- Open Access
- 8 October 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e63176
Investigating Exposure and Hazards of Micro- and Nanoplastics During Pregnancy and Early Life (AURORA Project): Protocol for an Interdisciplinary Study
Background: Micro- and nanoplastics (MNPs) are emerging pollutants of concern with ubiquitous presence in global ecosystems. MNPs pose potential implications for human health; however, the health impacts of MNP exposures are not yet understood. Recent evidence suggests that MNPs can cross the placental barrier, underlying the urgent need to understand their impact on reproductive health and development. Objective: The Actionable eUropean ROadmap for early-life health Risk Assessment of micro- and nanoplastics (AURORA) project will investigate MNP exposures and their biological and health effects during pregnancy and early life, which are critical periods due to heightened vulnerability to environmental stressors. The AURORA project will enhance exposure assessment capabilities for measuring MNPs, MNP-associated chemicals, and plastic additives in human tissues, including placenta and blood. Methods: In this interdisciplinary project, we will advance methods for in-depth characterization and scalable chemical analytical strategies, enabling high-resolution and large-scale toxicological, exposure assessment, and epidemiological studies. The AURORA project performs observational studies to investigate determinants and health impacts of MNPs by including 800 mother-child pairs from 2 existing birth cohorts and 110 women of reproductive age from a newly established cohort. This will be complemented by toxicological studies using a tiered-testing approach and epidemiological investigations to evaluate associations between maternal and prenatal MNP exposures and health perturbations, such as placental function, immune-inflammatory responses, oxidative stress, accelerated aging, endocrine disruption, and child growth and development. The ultimate goal of the AURORA project is to create an MNP risk assessment framework and identify the remaining knowledge gaps and priorities needed to comprehensively assess the impact of MNPs on early-life health. Results: In the first 3 years of this 5-year project (2021-2026), progress was made toward all objectives. This includes completion of recruitment and data collection for new and existing cohorts, development of analytical methodological protocols, and initiation of the toxicological tiered assessments. As of September 2024, data analysis is ongoing and results are expected to be published starting in 2025. Conclusions: As plastic pollution increases globally, it is imperative to understand the impact of MNPs on human health, particularly during vulnerable developmental stages such as early life. The contributions of the AURORA project will inform future risk assessment. International Registered Report Identifier (IRRID): DERR1-10.2196/63176
- 8 October 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e63176
Open AccessInvestigating Exposure and Hazards of Micro- and Nanoplastics During Pregnancy and Early Life (AURORA Project): Protocol for an Interdisciplinary Study
Background: Micro- and nanoplastics (MNPs) are emerging pollutants of concern with ubiquitous presence in global ecosystems. MNPs pose potential implications for human health; however, the health impacts of MNP exposures are not yet understood. Recent evidence suggests that MNPs can cross the placental barrier, underlying the urgent need to understand their impact on reproductive health and development. Objective: The Actionable eUropean ROadmap for early-life health Risk Assessment of micro- and nanoplastics (AURORA) project will investigate MNP exposures and their biological and health effects during pregnancy and early life, which are critical periods due to heightened vulnerability to environmental stressors. The AURORA project will enhance exposure assessment capabilities for measuring MNPs, MNP-associated chemicals, and plastic additives in human tissues, including placenta and blood. Methods: In this interdisciplinary project, we will advance methods for in-depth characterization and scalable chemical analytical strategies, enabling high-resolution and large-scale toxicological, exposure assessment, and epidemiological studies. The AURORA project performs observational studies to investigate determinants and health impacts of MNPs by including 800 mother-child pairs from 2 existing birth cohorts and 110 women of reproductive age from a newly established cohort. This will be complemented by toxicological studies using a tiered-testing approach and epidemiological investigations to evaluate associations between maternal and prenatal MNP exposures and health perturbations, such as placental function, immune-inflammatory responses, oxidative stress, accelerated aging, endocrine disruption, and child growth and development. The ultimate goal of the AURORA project is to create an MNP risk assessment framework and identify the remaining knowledge gaps and priorities needed to comprehensively assess the impact of MNPs on early-life health. Results: In the first 3 years of this 5-year project (2021-2026), progress was made toward all objectives. This includes completion of recruitment and data collection for new and existing cohorts, development of analytical methodological protocols, and initiation of the toxicological tiered assessments. As of September 2024, data analysis is ongoing and results are expected to be published starting in 2025. Conclusions: As plastic pollution increases globally, it is imperative to understand the impact of MNPs on human health, particularly during vulnerable developmental stages such as early life. The contributions of the AURORA project will inform future risk assessment. International Registered Report Identifier (IRRID): DERR1-10.2196/63176